Every Cure’s Post

Every Cure reposted this

View profile for David Fajgenbaum, MD, MBA, MSc, graphic

Physician-Scientist @ UPenn | National Bestselling Author, Chasing My Cure | Co-Founder @ Every Cure & CDCN

Novel drug development often feels like starting at your own 1-yard line, facing a daunting 99-yard drive with only a 10% chance of reaching the end zone. The journey is long and expensive, requiring years of research, clinical trials, and regulatory hurdles before even beginning to make an impact. The odds are stacked against us, and many promising drugs never reach their potential. 
In contrast, repurposing existing drugs is like beginning on the opponent's 5-yard line—much closer to making a meaningful difference. The drug is already developed, its safety profile is well established, and it’s ready to be tested in new ways.
 While repurposing may not yield the same financial rewards as developing a new blockbuster drug, it offers the potential to change lives more quickly than traditional pathways, leveraging existing knowledge and data to deliver effective therapies when they are needed most. At Every Cure, we are committed to seizing these opportunities and ensuring that no patient is ever told, “We’ve tried everything,” when a lifesaving cure may be sitting on the pharmacy shelf.
 Join us in our mission to unlock the potential of existing medications for all patients! #drugdevelopment #drugsaftey #drugdiscovery #pharma

Sundeep Dugar

President/CEO at Aayam Therapeutics leading innovative pharmaceutical research

2mo

Do we know if there has been a controlled trial with Rapamycin in patients with Castleman?

To view or add a comment, sign in

Explore topics